Comparative analysis of complement C3 and C4 serum levels for outcome prediction in ANCA-associated renal vasculitis

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small vessel vasculitis affecting multiple organ systems, including the kidney. Small vessels in the kidney include small-sized arteries, capillaries, and venules. Disease manifestations in the kidney are common and usually characterized by pauci-immune glomerulonephritis with only minor, if any, immunoglobulin and complement depositions in the vascular system. On a mechanistic level, pathogenic ANCA autoantibodies activate neutrophils, causing a release of inflammatory cytokines, reactive oxygen species, and lytic enzymes, resulting in inflammation and vascular injury. The activation of the complement system contributes essentially to the pathogenesis of ANCA-associated renal vasculitis by autoantibody-antigen recognition directed against host cells [1]. Activation of the complement system induces neutrophil adhesion and formation of neutrophil-platelet aggregates in vascular endothelial cells, implicating a direct mechanistic link between complement activation and vascular injury [1]. The measurement of serum complement C3 and C4 with immunoassays is routinely used in clinical practice to determine and monitor complement activation. Importantly, low serum complement C3 levels without hypocomplementemia per se are an independent predictor of poor renal prognosis in patients with ANCA-associated renal vasculitis [2‐5]. By contrast, low serum complement C4 levels alone were not associated with renal outcome [2]. However, serum levels of complement C4 have not been directly compared and analyzed in combination with serum C3 levels. Therefore, we here aimed to directly compare levels of C3 and C4 with regard to its clinical implications in ANCA-associated renal vasculitis.

While only 4/38 (10.5%) patients had hypocomplementemia with C4 levels below the normal range (< 0.15 g/L), patients who required KRT (13/38) or died (1/38) tended to have lower C4 (p = 0.0791, Fig. 1A). Low complement C4 below median serum levels (< 0.26 g/L) was only associated with older age, whereas kidney function, ANCA subtype, relapsing disease, systemic vasculitis activity, or classification of ANCA-associated renal vasculitis did not differ (Table 2). By contrast, low complement C3 below median levels (< 1.3 g/L) correlated with kidney injury requiring KRT within a follow-up of 40 days after diagnosis (p = 0.0167), not associated with any histopathological lesion or subtyping of ANCA-associated renal vasculitis (Table 3). Among 25/38 (65.8%) with low serum levels of C3 and/or C4, most cases of ANCA-associated renal vasculitis showed an overlap of low C3 and C4 levels (52%), and there were subsets of patients with isolated C4 lowering (24%, Fig. 1B). Direct comparison of serum complement C3 and C4 levels confirmed a positive association with each other (Fig. 1C). As compared to previously described prediction of poor outcome by low levels of complement C3 (p = 0.0093), low levels of complement C4 did not associate with early requirement of KRT or death within a follow-up of 40 days after diagnosis (p = 0.2396, Fig. 1D) [3]. Combined C3 and/or C4 effectively predicted poor outcome (p = 0.0134, Fig. 1E), while direct comparison revealed no superiority of low C3 and/or C4 as compared to low complement levels of C3 alone (Fig. 1F). In the subgroup that experienced KRT or death, low serum complement C3 levels identified 11/14 (78.6%, p = 0.0071) and complement C4 levels 9/14 (64.3%, p = 0.1786) cases (Fig. 1G). Interestingly, 2/14 (14.3%) patients that experienced KRT or death had isolated C4 lowering, and combining low serum levels of C3 and/or C4 identified 13/14 (92.3%, p < 0.0001) cases in this subgroup (Fig. 1G). Non-superiority to predict poor outcome by low C3 and/or C4 as compared to low complement levels of C3 alone in the total cohort was attributed to a subset of 4/24 (16.7%) patients with isolated C4 lowering in the subgroup that did not experience KRT or death (Fig. 1H). In summary, this comparative analysis revealed superiority in predicting poor outcome by low levels of complement C3 as compared to C4 in ANCA-associated renal vasculitis. However, a minor fraction that experienced KRT or death had isolated C4 lowering not captured by serum C3 measurements.

Low serum complement C3 levels without hypocomplementemia per se are an independent predictor of poor renal prognosis in patients with ANCA-associated renal vasculitis [2]. We performed a comparative analysis with regard to serum C3 and C4 levels to test its clinical implications in ANCA-associated renal vasculitis. As observed for levels of C3, we identified C4 hypocomplementemia only in a minor subset. As previously described, we defined low serum C4 according to median levels and identified no association with risk of KRT requirement or death in ANCA-associated renal vasculitis [2]. While most cases of ANCA-associated renal vasculitis showed an overlap of low complement C3 and C4 levels, there were subsets of patients with isolated C4 lowering. As compared to previously described prediction of poor outcome by low levels of complement C3, low levels of complement C4 did not associate with KRT or death. Interestingly, a minor fraction that experienced KRT or death had isolated C4 lowering not captured by serum C3 measurements. These observations implicate overlapping, but also independent roles of complement C3 and C4 that might contribute to kidney injury in ANCA-associated renal vasculitis. This is in line with our previous observation in this cohort that low levels of either serum C3 or C4 correlated with distinct inflammatory lesions in ANCA-associated renal vasculitis [10]. Regarding potential clinical implications, low serum levels of C3 were associated with renal injury as previously and independently described [2‐5]. In contrast, low levels of complement C4 were associated with older age in ANCA-associated renal vasculitis independent of kidney function, ANCA subtype, relapsing disease, systemic vasculitis activity, or classification of ANCA-associated renal vasculitis. While a relationship between age and distinct complement components has already been described in studies of healthy populations, this has not yet been observed in ANCA-associated renal vasculitis [15]. Its relevance related to age and treatment response remains elusive and requires further investigation. Currently, two C5a inhibitors are in clinical development for AAV: the oral C5a receptor (C5aR) inhibitor avacopan and the monoclonal C5a antibody IFX-1 [16]. Safety and efficacy with steroid-sparing effects of avacopan in patients with GPA/MPA have already been shown [16]. Furthermore, IFX-1 has entered Phase II development [16]. Therefore, detailed knowledge of distinct complement components contributing to kidney injury could be of relevance to further improve current strategies targeting the complement system, which is especially relevant in severe ANCA-associated renal vasculitis [17, 18].

The main limitations of our study are its retrospective design and the small patient number. Furthermore, we only assessed outcome during the initial course of ANCA-associated renal vasculitis requiring validation in independent cohorts also regarding long-term renal and overall outcome. Nevertheless, our observation that a minor fraction with isolated C4 lowering was not captured by serum C3 measurements implies overlapping, but also independent roles of complement C3 and C4 in ANCA-associated renal vasculitis. Therefore, a detailed analysis of intrarenal complement C4 deposition in comparison with C3 deposits among other histopathological lesions would be of relevance to gain further insights into the role of distinct complement components in ANCA-associated renal vasculitis.